The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.
Another such clinical-stage contender generating growing excitement is Intellia Therapeutics (NTLA), a CRISPR/Cas9-based gene-editing company. Intellia aims to provide one-time, curative treatments for serious genetic diseases. Intellia's stock has fallen 1.9% year-to-date, while the broader market, as tracked by the S&P 500 Index ($SPX), has risen 6%.
This Analyst Just Raised His Broadcom Stock Price Target by 70%. Should You Buy AVGO Now?
Why Alibaba Stock Looks Like a Screaming Buy After Falling 27% From Its 2025 Highs
2 ETFs Offering Juicy Dividend Yields of 20% or Higher
Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines.
Let's dig deeper to see if this could be the next transformative biotech story that reshapes medicine — and markets — in the same way Moderna did.
Intellia employs a dual-platform strategy, focusing on both in vivo (inside the patient's body) and ex vivo (outside the patient's body) approaches to treating conditions such as transthyretin amyloidosis (ATTR) and hereditary angioedema (HAE). Intellia's lead in vivo therapies include NTLA-2001 (Nexiguran ziclumeran or nex-z), a treatment for ATTR amyloidosis that is in the Phase 3 MAGNITUDE trial. Nex Z was also granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA), indicating its potential for accelerated development.
NTLA-2002, a treatment for hereditary angioedema (HAE), is now in late-stage clinical trials. In the first quarter of 2025, Intellia administered the first dose in the HAELO trial. This event marks a critical inflection point, bringing Intellia closer to regulatory filings and possible approval. However, the company recently halted its NTLA-3001 lung disease candidate, as well as several other research programs. It also reduced its workforce by about 27%, causing a short-term disruption. The goal of this strategic reorganization is to increase focus on late-stage assets while conserving capital.
While Intellia does not yet generate product revenue, it did generate $16.6 million in collaboration revenue during the first quarter. As of Q1 end, the company held $707.1 million in cash and executed a 27% workforce reduction, ensuring a runway until the first half of 2027.
Intellia's first-mover advantage in in vivo gene editing could propel it to great success if its candidates are approved. The company has also collaborated with heavyweights like Regeneron (REGN), gaining expertise, resources, and a broader clinical reach.
However, as a clinical-stage biotech company, the company faces the risk of clinical trials failing or delays in regulatory approvals because gene editing is a high-stakes game. Furthermore, increased cash burn may necessitate dilution. Long-term growth investors who believe in CRISPR's transformative potential may view NTLA stock as an enticing but high-risk investment opportunity.
Overall, Wall Street has assigned Intellia stock a 'Moderate Buy' rating. Of the 27 analysts covering NTLA stock, 19 have a 'Strong Buy' recommendation, one suggests a 'Moderate Buy,' six say it is a 'Hold,' and one suggests a 'Strong Sell.' The average price target of $38.04 implies the stock has upside potential of 245% over current levels. Plus, the Street-high price estimate of $106 suggests the stock can rally over 860% over the next 12 months.
While the upside appears out of reach, Moderna stock is a prime example of how a single successful product can propel a biotech stock toward the skies. Intellia, like Moderna, focuses on diseases with high clinical need and, if successful, has the potential to transform medicine.
On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Heavy-Duty Earnings Week Commences
We tiptoe into one of the busiest weeks of the year — not only because Q2 earnings season shifts into a higher gear, but because this is the week that gives us a new Federal Open Market Committee (FOMC) meeting and Personal Consumption Expenditures (PCE) report (PCE is the Fed's preferred gauge on inflation). It's also Jobs Week, because June JOLTS, ADP ADP private-sector payrolls for July, Weekly Jobless Claims and the always-important Employment Situation report from the U.S. Bureau of Labor Statistics (BLS). Q2 Earnings Outlook This Week Again, we're starting slow in this busy week, but Q2 earnings season sets up to bring us four of the 'Magnificent 7' stock earnings reports between now and Thursday afternoon: Microsoft MSFT and Meta Platforms META on Wednesday after the bell and Apple AAPL and Amazon AMZN a day later. We'll see Cadence Design Systems CDNS and Whirlpool WHR report after today's closing bell. This week also brings us important mainstays on the earnings front such as Procter & Gamble PG, Starbucks SBUX and Visa V tomorrow, Ford F and Qualcomm QCOM Wednesday and ExxonMobil XOM Friday morning. In all, 164 companies of the S&P 500 will have posted earnings results by Friday, August 1st. Fed Unlikely to Lower Rates on Wednesday Despite President Trump's long and very visible campaign to change Fed Chair Jerome Powell's mind about the ongoing Fed funds rate — it's been at +4.25-4.50% since December of last year, meaning for the entirely of Trump's second term so far — due to a relative equilibrium having been reached in the Fed's dual mandate. An Unemployment Rate of +4.1% and an Inflation Rate at +2.7% (up from +2.3% reached a couple months ago) demonstrate current rates are having their desired effect. That said, Fed Governors Chris Waller and Miki Bowman are likely to file the first dissents in some time from the ongoing narrative about interest rates at the conclusion of the upcoming FOMC meeting Wednesday afternoon. There's only a 2% chance the Fed has enough votes to cut to outstrip Powell's opinion to keep interest rates where they are. After an August break, September's odds go up to +67% for a 25 basis-point (bps) cut. This is expected to once again raise Trump's hackles, although perhaps his early-week successes — a trade deal with the EU and ongoing negotiations with China in Stockholm, Sweden — will soothe the president somewhat. Any big, unexpected changes to PCE or the labor market this week — say a sub-100K read on monthly employment, a negative Q2 GDP or a near-+3% year over year PCE — will happen too late for the Fed to pivot on its final decision on rates this summer. Labor Market Solid… but Weakening? We don't see it in continually shrinking Initial Jobless Claims per week (back down to 217K last Thursday), but this week's jobs figures ought to help answer several questions raised in last week's Jobs Week reports: ADP private sector payrolls posted a negative -33K jobs filled in June, the first negative print in more than two years. And, while that Friday's subsequent BLS report came in at +147K, more than half of those new jobs came from State & Local Government. What that means is that only around 70K new jobs were filled in June outside government hires; 70K isn't enough to cover the monthly deluge of retiring Baby Boomers and older GenX. So another leg down here — as well as a Continuing Jobless Claims tally closing in on 2 million per week — would change the narrative of the U.S. having a strong labor market, thereby reviving the idea that the Fed needs to cut rates. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN) : Free Stock Analysis Report Ford Motor Company (F) : Free Stock Analysis Report QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report Apple Inc. (AAPL) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report Visa Inc. (V) : Free Stock Analysis Report Automatic Data Processing, Inc. (ADP) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Procter & Gamble Company (The) (PG) : Free Stock Analysis Report Starbucks Corporation (SBUX) : Free Stock Analysis Report Whirlpool Corporation (WHR) : Free Stock Analysis Report Cadence Design Systems, Inc. (CDNS) : Free Stock Analysis Report Meta Platforms, Inc. (META) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Sugar Prices Supported by Strength in Crude Oil
October NY world sugar #11 (SBV25) today is up +0.08 (+0.49%), and October London ICE white sugar #5 (SWV25) is up +1.30 (+0.28%). Sugar prices are rising today as a rally in crude oil prices has sparked short covering in sugar futures. WTI crude oil (CLU5) is up more than +2% today to a 1-week high, which benefits ethanol prices and may prompt the world's sugar mills to divert cane crushing toward ethanol production rather than sugar, thus curbing sugar supplies. More News from Barchart Does the 2025 Corn Crop Have a Pollination Problem? Weather Shocks vs. Oversupply: Are You Trading SRW Wheat's Next Big Move? Adverse Brazilian Weather and Tariff Concerns Boost Coffee Prices Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Last Wednesday, sugar prices fell to 3-week lows after Bloomberg reported that India may permit local sugar mills to export sugar in the next season, which starts in October, as abundant monsoon rains may produce a bumper sugar crop. India's Meteorological Department reported Monday that cumulative monsoon rain in India is 6% above normal as of July 21. The outlook for higher sugar production in Brazil is bearish for sugar prices. Datagro said Monday that dry weather in Brazil has encouraged the country's sugar mills to increase their cane crushing, diverting more of the cane crush toward more profitable sugar production rather than ethanol. According to Covrig, Brazil's sugar mills are expected to crush 54% of the available cane in the first half of this month, likely adding 3.2 MMT of sugar into the market. The outlook for higher sugar production in India, the world's second-largest producer, is bearish for prices. On June 2, India's National Federation of Cooperative Sugar Factories projected that India's 2025/26 sugar production would climb +19% y/y to 35 MMT, citing larger planted cane acreage. That would follow a -17.5% y/y decline in India's sugar production in 2024/25 to a 5-year low of 26.2 MMT, according to the Indian Sugar Mills Association (ISMA). Also, the ISMA reported on July 7 that India's sugar production during Oct 1-May 15 fell -17% y/y to 25.74 MMT. Sugar prices have retreated over the past three months, with NY sugar falling to a 4.25-year low earlier this month and London sugar sliding to a nearly 4-year low, driven by expectations of a sugar surplus in the 2025/26 season. On June 30, commodities trader Czarnikow projected a 7.5 MMT global sugar surplus for the 2025/26 season, the largest surplus in 8 years. On May 22, the USDA, in its biannual report, projected that global 2025/26 sugar production would increase by +4.7% y/y to a record 189.318 MMT, with global sugar ending stocks at 41.188 MMT, up 7.5% y/y. Signs that the recent slide in sugar prices to 4-year lows has sparked a pickup in demand are positive for sugar prices. China's June sugar imports soared by 1,435% to 420,000 MT. Also, President Trump last Wednesday said Coca-Cola agreed to use cane sugar in Coke beverages sold in the US instead of high-fructose corn syrup, which could boost US sugar consumption by +4.4% to 11.5 MMT from 11 MMT currently, according to Bloomberg Intelligence. Sugar prices also have support from reduced sugar production in Brazil. Unica reported last Monday that the cumulative 2025/26 Brazil Center-South sugar output through June fell by -14.3% y/y to 12.249 MMT. Last month, Conab, Brazil's government crop forecasting agency, said 2024/25 Brazil sugar production fell by -3.4% y/y to 44.118 MMT, citing lower sugarcane yields due to drought and excessive heat. The outlook for higher sugar production in Thailand is bearish for sugar prices. On May 2, Thailand's Office of the Cane and Sugar Board reported that Thailand's 2024/25 sugar production rose +14% y/y to 10.00 MMT. Thailand is the world's third-largest sugar producer and the second-largest exporter of sugar. The International Sugar Organization (ISO) raised its 2024/25 global sugar deficit forecast to a 9-year high of -5.47 MMT on May 15, up from a February forecast of -4.88 MMT. This indicates a tightening market following the 2023/24 global sugar surplus of 1.31 MMT. ISO also cut its 2024/25 global sugar production forecast to 174.8 MMT from a February forecast of 175.5 MMT. The USDA, in its bi-annual report released May 22, projected that global 2025/26 sugar production would climb +4.7% y/y to a record 189.318 MMT and that global 2025/26 human sugar consumption would increase +1.4% y/y to a record 177.921 MMT. The USDA also forecasted that 2025/26 global sugar ending stocks would climb +7.5% y/y to 41.188 MMT. The USDA's Foreign Agricultural Service (FAS) predicted that Brazil's 2025/26 sugar production would rise +2.3% y/y to a record 44.7 MMT FAS predicted that India's 2025/26 sugar production would rise +25% y/y to 35.3 MMT due to favorable monsoon rains and increased sugar acreage. FAS predicted that Thailand's 2025/26 sugar production will climb +2% y/y to 10.3 MMT. On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Best Buy Earnings Preview: What to Expect
With a market cap of $14.3 billion, Best Buy Co., Inc. (BBY) is a leading multinational retailer specializing in consumer electronics, appliances, and related services, operating in the United States and Canada. The company offers a wide range of technology products and support through its physical stores and online platforms under various brand names, including Best Buy, Geek Squad, and Lively. The Richfield, Minnesota-based company is expected to announce its fiscal Q2 2026 earnings results on Thursday, Sept. 4. Ahead of this event, analysts expect Best Buy to report an adjusted EPS of $1.22, down nearly 9% from $1.34 in the year-ago quarter. It has surpassed Wall Street's earnings estimates in three of the last quarters while missing on another occasion. More News from Barchart Warren Buffett Warns Inflation Turns Business Into 'The Upside-Down World of Alice in Wonderland' But Weeds Out 'Bad Businesses' Why GOOGL Stock May Be the Market's Next Big Winner Alphabet Posts Lower Free Cash Flow and FCF Margins - Is GOOGL Stock Overvalued? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For fiscal 2026, analysts expect the consumer electronics retailer to report an adjusted EPS of $6.22, a 2.4% decline from $6.37 in fiscal 2025. However, adjusted EPS is anticipated to grow 8.2% year-over-year to $6.73 in fiscal 2027. Shares of Best Buy have declined 21.6% over the past 52 weeks, underperforming both the S&P 500 Index's ($SPX) 17.1% gain and the Consumer Discretionary Select Sector SPDR Fund's (XLY) 24.3% return over the period. Despite posting a better-than-expected Q1 2026 adjusted EPS of $1.15, Best Buy shares tumbled 7.3% on May 29 due to a significant cut in its full-year comparable sales and adjusted EPS guidance to $6.15 - $6.30. Investor sentiment was further dampened by concerns over rising U.S. tariffs, which could increase costs on imported goods, roughly 30% - 35% of Best Buy's inventory, pressuring margins and consumer demand for high-ticket items. Analysts' consensus view on BBY stock is cautiously optimistic, with a "Moderate Buy" rating overall. Among 22 analysts covering the stock, eight recommend "Strong Buy," 13 indicate 'Hold,' and one advises "Moderate Sell." As of writing, the stock is trading below the average analyst price target of $78.42. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
